SCHEMBL15716636

SCHEMBL15716636

CC(Oc1cncc(B(O)O)c1)c1ccccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.38
▸ CREBBP Q92793 1/20 0.38
▸ CYP3A4 P08684 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ NOX1 Q9Y5S8 2/20 0.35
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ KMO O15229 5/20 0.34
▸ TSHR P16473 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ABCB11 O95342 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ ADRA2A P08913 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15716635 1.00 BRD4 (0.38) BRD4CREBBPCYP3A4CYP1A2POLB
SCHEMBL15716702 0.81 FFAR1 (0.40) ADRA2A
SCHEMBL15716819 0.80 BRD4 (0.40) BRD4CREBBPCYP3A4CYP1A2POLB
SCHEMBL15716816 0.80 BRD4 (0.40) BRD4CREBBPCYP3A4CYP1A2POLB
SCHEMBL15716967 0.76 KCNA5 (0.36) BRD4CREBBPCYP3A4CYP1A2POLB
SCHEMBL2083713 0.75 CHRNB2 (0.40) BRD4CREBBPCYP3A4LMNA
SCHEMBL10697880 0.73 POLB (0.58) BRD4CREBBPCYP3A4CYP1A2POLB
SCHEMBL27967203 0.71 BRD4 (0.44) BRD4CREBBPCYP3A4POLBTSHR
SCHEMBL27967202 0.71 BRD4 (0.44) BRD4CREBBPCYP3A4POLBTSHR
SCHEMBL30318847 0.70 KMO (0.36) BRD4CREBBPGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 — — US disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 — — US disclosed
US-9663533-B2 Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors GLAXOSMITHKLINE LLC (US) 2017-05-30 — — US disclosed
EP-2920183-B1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2017-03-08 — — EP disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC 2016-10-13 — — US disclosed
EP-2920183-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS Glaxosmithkline LLC (US) 2015-09-23 — — EP disclosed
WO-2014078257-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-05-22 — — WO disclosed
US-20110217750-A1 Dendrimers and Dendrimer Applications NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) 2011-09-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297832-A1 THIENO[3,2-C]PYRIDIN-4(5H)-ONES AS BET INHIBITORS BRD4, BET1, BRD3 BRD4 1/4885CREBBP 25/4885CYP3A4 2101/4885
US-20110217750-A1 Dendrimers and Dendrimer Applications ADH1A, DNPH1, SAMHD1 BRD4 2449/4885CREBBP 4520/4885CYP3A4 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback